• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Liontrust UK Opportunities Fund C Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Liontrust Investment Management Limited
Fund Summary The investment objective of Liontrust UK Opportunities Fund is to generate long term (5 years or more) capital growth. The Fund invests at least 80% in shares of UK companies. These are companies which, at the time of purchase, are incorporated, domiciled or conduct significant business in the UK. The Fund may also invest up to 20% in companies outside of the UK, as well as in other eligible asset classes. Other eligible asset classes are collective investment schemes (which may include Liontrust managed funds), other transferable securities, cash or near cash, deposits and money market instruments. Derivatives and forward transactions may be used by the ACD for efficient portfolio management. It is the intention to be near-fully invested at all times, however, the Fund has the facility to take tactical positions in cash or near cash, and to use efficient portfolio management, should the ACD feel it appropriate. The portfolio will be managed to ensure that the Fund is at all times eligible to qualify for, and to be included in, an Individual Savings Account.
SEDOL code B8L76S5
ISIN GB00B8L76S53
Fund code NPSPA
Managers Mark Martin
Manager Tenure 4 years
Morningstar Category UK Flex-Cap Equity
IMA Sector UK All Companies
Fund Size £11 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.95%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £1.6360
Buy Price £1.6360
Price Change +0.9254%
Price Date 12th November 2019
Yield 2.45%
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 29th April 2013
Fund Status OPEN
Mark is an Investment Director and Head of UK Equities. Areas of expertise include UK mid & small caps and global healthcare research. Before joining Neptune, Mark qualified as a solicitor at Allen & Overy in the Private Equity group, having graduated from Oxford University with a degree in Classics.

3-year Mean Monthly Return: 0.188%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance -5.44% -0.64% +14.83% +5.57% +5.82% +8.59% +25.20% +22.69% -4.07% +7.06%
Benchmark Performance
(UK Flex-Cap Equity)
-1.47% +6.31% +15.07% +11.37% +3.92%
Time Period Cumulative Benchmark Performance
(UK Flex-Cap Equity)
Fund Compared to Benchmark
1 day -0.31% +15.05% -15.36%
1 week 2.21% +2.49% -0.28%
1 month 4.58% +3.70% +0.88%
3 months 3.38% +2.56% +0.82%
6 months 0.75% +6.17% -5.42%
1 year 6.09% +6.76% -0.68%
3 years 2.87% +6.82% -3.94%
5 years 3.77% +9.04% -5.27%
10 years 7.77% +5.97% +1.80%
YTD 11.95% -0.36% +12.31%
Since inception 6.10% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
PureTech Health PLC USA 9.32%
Chemring Group PLC GBR 8.88%
Elementis PLC GBR 8.83%
Devro PLC GBR 6.66%
Essentra PLC GBR 4.58%
De La Rue PLC GBR 4.49%
Morgan Advanced Materials PLC GBR 4.38%
Vectura Group PLC GBR 4.37%
Ricardo PLC GBR 4.22%
Oxford Instruments PLC GBR 4.07%
Dividend Date Per share amount Reinvestment Price
2nd January 2019 0.0393 £1.4530
2nd January 2018 0.0143 £1.7450
3rd July 2017 0.0214 £1.6510
3rd January 2017 0.0133 £1.5590
1st July 2016 0.0170 £1.3860
4th January 2016 0.0114 £1.4250